Climb Bio Inc (CLYM) Stock Price, Quote & News

Company Profile

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclo...

Industry: Biotechnology

Sector: Healthcare

Phone: 866 857 2596

Website: climbbio.com

Address:

20 William Street, Suite 145, Wellesley Hills, United States

Invest2live Oct. 24 at 10:11 PM

$OPEN 190% already; congrats 🎉 🎈🎊 Checkout $CLYM and $RXRX similar potential

0 · Reply

Invest2live Oct. 22 at 8:54 PM

$ASRT $IBIO $REKR $IBIO 80% in a few days; congrats 🎈 🌿🎉 Checkout $RXRX and $CLYM

0 · Reply

Fakhrul123 Oct. 22 at 7:11 AM

$CLYM $3 this week!!!

0 · Reply

Invest2live Oct. 21 at 3:05 PM

$NERV 327% in less than 2 months; congrats 🎊 🌿 🎉 Checkout $CLYM with similar potential as well as $LCTX for longs. Do your DD and get in.

1 · Reply

Invest2live Oct. 21 at 1:53 PM

$CLYM $IBIO $NGD $IBIO 50% already; congrats 🎊 🌿🎈 Checkout $CLYM and $CUE and $LCTX

0 · Reply

Invest2live Oct. 21 at 1:39 PM

$NERV 190% already; congrats 🎊 🌿🎈 Checkout $LCTX and $CLYM as well as $I.XBiO

0 · Reply

Fakhrul123 Oct. 20 at 10:55 PM

$CLYM $3 in this week

0 · Reply

_www_larval_com_ Oct. 20 at 7:48 PM

$CLYM has jumped 4% higher to 19% (~1Mv) a few minutes ago, follow for more volatility.

0 · Reply

Chumpchange53 Oct. 20 at 4:11 PM

$CLYM BOOOOOOOOYAAAAAAAAAAA!!!!!!!

0 · Reply

Quantumup Oct. 17 at 6:22 PM

H.C. Wainwright on 10/13, 🏁 $CLYM at a Buy-$9, and said, A Next-Generation Developer of Therapies for Autoimmune B Cell-Mediated Diseases. We are initiating coverage of Climb Bio with a Buy rating and 12-month price target of $9 per share. H.C. Wainwright additionally said:

0 · Reply

Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy

Oct 17, 2025, 7:00 AM EDT - 8 days ago

Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025

Oct 1, 2025, 7:00 AM EDT - 24 days ago

Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer

Sep 29, 2025, 7:00 AM EDT - 26 days ago

Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN

Sep 4, 2025, 7:00 AM EDT - 7 weeks ago

Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025

Aug 25, 2025, 2:41 PM EDT - 2 months ago

UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences

Aug 25, 2025, 7:00 AM EDT - 2 months ago

Climb Bio to Present at Upcoming September 2025 Investor Conferences

Aug 12, 2025, 7:00 AM EDT - 2 months ago

Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

May 19, 2025, 4:34 PM EDT - 5 months ago

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 14, 2025, 7:00 AM EDT - 5 months ago

Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 1, 2025, 7:00 AM EDT - 7 months ago

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Mar 27, 2025, 7:00 AM EDT - 7 months ago

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 25, 2025, 4:05 PM EDT - 7 months ago

Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates

Feb 25, 2025, 7:00 AM EST - 8 months ago

Climb Bio to Present at Upcoming Investor Conferences

Feb 24, 2025, 7:00 AM EST - 8 months ago

Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer

Feb 4, 2025, 7:00 AM EST - 9 months ago

Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 9, 2025, 7:00 AM EST - 10 months ago

Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy

Dec 19, 2024, 7:00 AM EST - 11 months ago

Climb Bio to be Added to the Nasdaq Biotechnology Index

Nov 12, 2024, 4:05 PM EST - 1 year ago

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 11, 2024, 7:00 AM EST - 1 year ago

Climb Bio Appoints Douglas E. Williams, Ph.D.

Oct 15, 2024, 7:00 AM EDT - 1 year ago

Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event

Oct 11, 2024, 12:30 PM EDT - 1 year ago

Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

Oct 4, 2024, 7:00 AM EDT - 1 year ago

Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19

Oct 3, 2024, 10:00 AM EDT - 1 year ago

Climb Bio to Host Virtual Investor Event on October 15, 2024

Oct 2, 2024, 9:00 AM EDT - 1 year ago

Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.

Sep 11, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit

Aug 26, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics Announces Additions to its Leadership Team

Aug 14, 2024, 6:05 AM EDT - 1 year ago

Eliem Therapeutics Reports Second Quarter Financial Results

Jun 28, 2024, 1:58 PM EDT - 1 year ago

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Jun 28, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes

Jun 27, 2024, 4:01 PM EDT - 1 year ago

Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

Jul 20, 2023, 6:57 AM EDT - 2 years ago

Eliem Therapeutics' stock soars 21% premarket after company says it may sell itself

Jul 20, 2023, 6:45 AM EDT - 2 years ago

Eliem Therapeutics Announces Plans to Explore Strategic Alternatives

May 11, 2023, 4:10 PM EDT - 2 years ago

Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights

Mar 6, 2023, 4:10 PM EST - 2 years ago

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights

Feb 9, 2023, 4:01 PM EST - 2 years ago

Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition

Nov 30, 2022, 7:00 AM EST - 3 years ago

Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference

Nov 14, 2022, 6:10 AM EST - 3 years ago

Eliem Therapeutics Reports Third Quarter Financial and Business Highlights

Nov 8, 2022, 7:00 AM EST - 3 years ago

Eliem Therapeutics to Participate at Two Upcoming Investor Conferences

Oct 5, 2022, 7:00 AM EDT - 3 years ago

Eliem Therapeutics Provides Update on Pipeline Progress

Aug 15, 2022, 6:10 AM EDT - 3 years ago

Eliem Therapeutics Reports Second Quarter Financial and Business Highlights

Aug 2, 2022, 9:33 AM EDT - 3 years ago

Eliem's stock slides 20% after saying it will discontinue development of pain treatment

Aug 2, 2022, 7:00 AM EDT - 3 years ago

Eliem Therapeutics Provides ETX-810 Program Update

Jul 18, 2022, 7:00 AM EDT - 3 years ago

Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder

Jul 7, 2022, 7:00 AM EDT - 3 years ago

Eliem Therapeutics to Host Virtual Investor Event on July 21, 2022

Jun 27, 2022, 4:01 PM EDT - 3 years ago

Eliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810 in Patients with Lumbosacral Radicular Pain (LSRP)

Invest2live Oct. 24 at 10:11 PM

$OPEN 190% already; congrats 🎉 🎈🎊 Checkout $CLYM and $RXRX similar potential

0 · Reply

Invest2live Oct. 22 at 8:54 PM

$ASRT $IBIO $REKR $IBIO 80% in a few days; congrats 🎈 🌿🎉 Checkout $RXRX and $CLYM

0 · Reply

Fakhrul123 Oct. 22 at 7:11 AM

$CLYM $3 this week!!!

0 · Reply

Invest2live Oct. 21 at 3:05 PM

$NERV 327% in less than 2 months; congrats 🎊 🌿 🎉 Checkout $CLYM with similar potential as well as $LCTX for longs. Do your DD and get in.

1 · Reply

Invest2live Oct. 21 at 1:53 PM

$CLYM $IBIO $NGD $IBIO 50% already; congrats 🎊 🌿🎈 Checkout $CLYM and $CUE and $LCTX

0 · Reply

Invest2live Oct. 21 at 1:39 PM

$NERV 190% already; congrats 🎊 🌿🎈 Checkout $LCTX and $CLYM as well as $I.XBiO

0 · Reply

Fakhrul123 Oct. 20 at 10:55 PM

$CLYM $3 in this week

0 · Reply

_www_larval_com_ Oct. 20 at 7:48 PM

$CLYM has jumped 4% higher to 19% (~1Mv) a few minutes ago, follow for more volatility.

0 · Reply

Chumpchange53 Oct. 20 at 4:11 PM

$CLYM BOOOOOOOOYAAAAAAAAAAA!!!!!!!

0 · Reply

Quantumup Oct. 17 at 6:22 PM

0 · Reply

Rick2058 Oct. 17 at 12:27 PM

$CLYM

0 · Reply

Rick2058 Oct. 17 at 12:19 PM

$CLYM Added some. Heavy volume. Plenty of cash. Average of eight analysts' price target $9.20.

0 · Reply

Invest2live Oct. 16 at 3:34 PM

$NGD 1009% already; congrats 🎊 🎈🎉 Checkout $CLYM and $IBIO, dark past but looking good now

0 · Reply

boomshiva Oct. 16 at 1:47 PM

$CLYM Starter position at 2.16.

0 · Reply

JarvisFlow Oct. 16 at 11:03 AM

William Blair has adjusted their stance on Climb Bio ( $CLYM ), setting the rating to Outperform.

0 · Reply

JarvisFlow Oct. 16 at 10:30 AM

BTIG updates rating for Climb Bio ( $CLYM ) to Buy, target set at 8.

0 · Reply

TeleHix Oct. 14 at 4:10 PM

$CLYM Huge transaction hit tape at 1.92

0 · Reply

Invest2live Oct. 14 at 3:10 PM

$NAK 524% already; congrats 🎈 🎉🎊 Checkout $CLYM and $HRMY

0 · Reply

Invest2live Oct. 13 at 8:14 PM

$PLX 153% already; congrats 🎉 🎈🎊 Checkout $CUE and $CLYM

0 · Reply

peepthestamp Oct. 13 at 4:41 PM

$CLYM

0 · Reply

JarvisFlow Oct. 13 at 11:21 AM

HC Wainwright & Co. has adjusted their stance on Climb Bio ( $CLYM ), setting the rating to Buy with a target price of 9.

0 · Reply

Fakhrul123 Oct. 8 at 12:15 PM

$CLYM

0 · Reply

Market Cap	134.85M
Revenue (ttm)	0.00
Net Income (ttm)	-73.90M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	495,500
Avg Vol	743,302
Day's Range	N/A - N/A
Shares Out	67.76M
Stochastic %K	29%
Beta	-0.07
Analysts	Strong Sell
Price Target	$9.20